Last week, RPX raised the possibility of IP Edge LLC’s practices—specifically, the naming of Texas residents with seemingly no discernible connections to patent monetization as managers or managing members of most of its LLCs—sliding under the judicial microscope. On September 12, District of Delaware Chief Judge Colm F. Connolly ordered a handful of such individuals to appear, in person, at evidentiary hearings to determine whether a group of apparent IP Edge plaintiffs has complied with his standing order regarding the disclosure of any third-party litigation funding. A similar order has been issued in multiple cases associated with Dynamic IP Deals, LLC (d/b/a DynaIP), Judge Connolly setting an October hearing to determine the accuracy of those plaintiffs’ amended corporate disclosure statements. Perhaps unsurprisingly, voluntary dismissals have been noticed across these cases, ending the court’s jurisdiction over the matters.

Evidence of IP Edge LLC’s frequent practice of naming individuals—seemingly with no discernible connections to patent monetization—as managers or managing members of its various LLCs has long been reported by RPX. Now, with Amazon having recently brought that practice to the attention of Chief Judge Colm F. Connolly, and with a raft of amended disclosures filed on the same day last week by a handful of apparent IP Edge plaintiffs litigating before that same judge, the coming months may see the full extent of that setup, and its bearing on standing, come to light.

RPX took notice, among the USPTO assignment records made available during the second half of August, of transfers to several frequent plaintiffs in litigation, including affiliates of Leigh M. Rothschild, IP Edge LLC, and Monument Patent Holdings, LLC.

Mirage IP LLC, an affiliate of Texas monetization firm IP Edge LLC, has launched a litigation campaign, asserting two medical device patents (6,375,629; 6,958,059). The ‘629 patent is asserted against AngioDynamics (2:17-cv-00377), Cook Medical Technologies (2:17-cv-00379), MS Holding (Biotronik) (2:17-cv-00378), St. Jude Medical (2:17-cv-00383), and Stryker (2:17-cv-00384) for the manufacture and sale of medical guidewires; the ‘059 patent, against Oscor (2:17-cv-00381) and Spectralytics (Spectranetics) (2:17-cv-00382) for the use of certain catheters; and the ‘629 and ‘059 patents, against Microvention (2:17-cv-00380) for the manufacture and sale of both guidewires and catheters. This campaign is IP Edge’s fifth of 2017 and the second to assert medical devices patents acquired from IP Navigation Group, LLC (d/b/a IPNav).